Prospective Multicenter Human Randomized Controlled Evaluation of NOTES® Cholecystectomy

NCT ID: NCT01171027

Last Updated: 2011-12-02

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-07-31

Study Completion Date

2012-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is designed to be a United States multicenter prospective randomized controlled non-inferiority evaluation of transgastric and transvaginal Natural Orifice Translumenal Endoscopic Surgery (NOTES) cholecystectomy compared to laparoscopic cholecystectomy in elective surgery patients. Up to 200 patients will be enrolled to obtain 70 NOTES cholecystectomies (35 transgastric and 35 transvaginal) and 70 laparoscopic cholecystectomies on a randomized basis. In order to evaluate the hypothesis that NOTES cholecystectomy has equivalent safety and efficacy to laparoscopic cholecystectomy, clinical and administrative outcomes will be measured.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Primary To assess the safety and efficacy of transgastric and transvaginal cholecystectomy compared to conventional laparoscopic cholecystectomy.

To assess pain associated with transgastric and transvaginal cholecystectomy compared to conventional laparoscopic cholecystectomy.

Secondary To assess cosmesis associated with transgastric and transvaginal cholecystectomy compared to conventional laparoscopic cholecystectomy.

To assess objective operative cost and logistical comparisons between transgastric and transvaginal cholecystectomy compared to conventional laparoscopic cholecystectomy.

To identify unforeseen barriers to transgastric or transvaginal surgery adoption.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Gall Bladder Diseases

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Cholecystectomy NOTES Transvaginal Transgastric Natural orifice Gallbladder removal

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

NOTES(R) Cholecystectomy

Natural Orifice Translumenal Endoscopic Surgery techniques

Group Type EXPERIMENTAL

NOTES Cholecystectomy

Intervention Type PROCEDURE

The transvaginal NOTES approach is accomplished by performing a posterior colpotomy. Instead of a conventional laparoscope, a flexible endoscope is used in order to provide working channels and visualization. The gallbladder is removed through the vaginal incision. The transgastric cholecystectomy requires the flexible endoscope to be placed orally. A gastrotomy is made through the stomach wall allowing the flexible endoscope to pass into the abdominal cavity. The gallbladder is removed from the abdominal cavity into the stomach and ultimately out the mouth. The goal of NOTES is to develop further so either of these approaches will not require any incisions in the abdominal wall.

Laparoscopic Cholecystectomy

Laparoscopic Cholecystectomy

Group Type ACTIVE_COMPARATOR

NOTES Cholecystectomy

Intervention Type PROCEDURE

The transvaginal NOTES approach is accomplished by performing a posterior colpotomy. Instead of a conventional laparoscope, a flexible endoscope is used in order to provide working channels and visualization. The gallbladder is removed through the vaginal incision. The transgastric cholecystectomy requires the flexible endoscope to be placed orally. A gastrotomy is made through the stomach wall allowing the flexible endoscope to pass into the abdominal cavity. The gallbladder is removed from the abdominal cavity into the stomach and ultimately out the mouth. The goal of NOTES is to develop further so either of these approaches will not require any incisions in the abdominal wall.

Laparoscopic Cholecystectomy

Intervention Type PROCEDURE

This technique utilizes the introduction of a laparoscope through a 1 cm incision in the fascia in or around umbilicus. Usually three additional 0.5- 1.0 cm incisions are employed for surgical instrumentation. Once separated from its attachments, the gallbladder is usually removed through the umbilical port. Sutures are used to close the larger port sites. The most devastating complication is injury to the major bile ducts which is avoided to the extent possible (incidence .2 to less than .01%)5 by careful visualization of the ductal structures.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

NOTES Cholecystectomy

The transvaginal NOTES approach is accomplished by performing a posterior colpotomy. Instead of a conventional laparoscope, a flexible endoscope is used in order to provide working channels and visualization. The gallbladder is removed through the vaginal incision. The transgastric cholecystectomy requires the flexible endoscope to be placed orally. A gastrotomy is made through the stomach wall allowing the flexible endoscope to pass into the abdominal cavity. The gallbladder is removed from the abdominal cavity into the stomach and ultimately out the mouth. The goal of NOTES is to develop further so either of these approaches will not require any incisions in the abdominal wall.

Intervention Type PROCEDURE

Laparoscopic Cholecystectomy

This technique utilizes the introduction of a laparoscope through a 1 cm incision in the fascia in or around umbilicus. Usually three additional 0.5- 1.0 cm incisions are employed for surgical instrumentation. Once separated from its attachments, the gallbladder is usually removed through the umbilical port. Sutures are used to close the larger port sites. The most devastating complication is injury to the major bile ducts which is avoided to the extent possible (incidence .2 to less than .01%)5 by careful visualization of the ductal structures.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Competent male or female subjects, between the ages of 18-75 and who present for elective cholecystectomy will be offered participation in this study.
* Male subjects must be willing to have the cholecystectomy by either the laparoscopic or transgastric NOTES approach.
* Female subjects must be willing to have the cholecystectomy by either the laparoscopic or either the NOTES approaches (transgastric and/or transvaginal) being performed at the site.
* Patients offered participation in this study must provide written, informed consent and meet the following criteria prior to randomization.
* Diagnosis of benign gallstone disease which requires cholecystectomy.
* ASA Class 1 or 2.
* Willingness to have laparoscopic cholecystectomy performed and have research data collected for control group.
* Willingness to have abdomen photographed (for cosmesis assessment).
* For sites performing transgastric NOTES approach

* Willingness to have cholecystectomy performed via NOTES transgastric approach.
* Willingness to have NOTES procedure videotaped.
* For sites performing transvaginal NOTES approach - Female subjects only

* Willingness to have cholecystectomy performed via NOTES transvaginal approach.
* Willingness to have intra-abdominal procedure digitally recorded.
* Pelvic examination in the past 12 months without significant pathology.

Exclusion Criteria

* Pregnant women.
* Obese patients (BMI \> 35).
* Patients with severe medical comorbidities (ie, NOT ASA Class 1 or 2) will be excluded such as:
* Chronic renal failure
* Chronic liver disease
* Congestive heart failure
* Patients with a presumed gallbladder malignancy.
* Patients with a history of prior open abdominal or laparoscopic or transvaginal surgery. However patients with prior appendectomy, tubal ligation or Cesarean section will be included.
* Patients who are taking immunosuppressive medications and/or immunocompromised.
* Patients with a prior history of perineal trauma leading to significant alteration of vaginal anatomy.
* Patients with a history of ectopic pregnancy, pelvic inflammatory disease, large fibroids or severe endometriosis.
* Patients with known common bile duct stones. (ie, not cleared prior to surgery). Patients with common bile duct stones discovered intra-operatively will remain in the study.
* Patients on anticoagulation drugs other than once daily aspirin. Abnormal blood coagulation tests. Minimal abnormalities may be allowed at the discretion of site principal investigator.
* Gallstones\> 2.5cm in diameter.
* Presence of untreated esophageal stricture.
* Surgically altered gastric anatomy or severe uncorrected paraesophageal types 2, 3 or 4.
* Unwillingness to consent to NOTES procedure(s).
* Acute cholecystitis or cholangitis
* For sites performing transgastric NOTES approach

* Contraindicated for esophagogastroduodenoscopy (EGD).
* Patients with hypersecretory states.
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

American Society for Gastrointestinal Endoscopy

OTHER

Sponsor Role collaborator

Natural Orifice Surgery Consortium for Assessment and Research

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Steven Schwaitzberg, MD

Role: PRINCIPAL_INVESTIGATOR

Cambridge Health Alliance

Michael L. Kochman, MD

Role: PRINCIPAL_INVESTIGATOR

University of Pennsylvania

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of California at San Diego

San Diego, California, United States

Site Status RECRUITING

Yale University

New Haven, Connecticut, United States

Site Status RECRUITING

Northwestern University

Chicago, Illinois, United States

Site Status RECRUITING

Baystate Medical Center

Springfield, Massachusetts, United States

Site Status RECRUITING

Ohio State University

Columbus, Ohio, United States

Site Status RECRUITING

Oregon Clinic

Portland, Oregon, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Michael Kochman, MD

Role: CONTACT

Phone: 215 662 4279

Email: [email protected]

Steven L Schwaitzberg, MD

Role: CONTACT

Phone: 617 665 3193

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Santiago Horgan, MD

Role: primary

Mark Talamini, MD

Role: backup

Kurt Roberts, MD

Role: primary

Eric Hungness, MD

Role: primary

John Romanelli, MD

Role: primary

David Earle, MD

Role: backup

Jeffrey Hazey, MD

Role: primary

Lee Swanstrom, MD

Role: primary

Related Links

Access external resources that provide additional context or updates about the study.

http://www.noscar.org

NOSCAR web site

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NOTES® Trial

Identifier Type: -

Identifier Source: org_study_id